Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion: A case report

Diabetes Care

Volumn 21, Issue 7, 1998, Pages 1044-1045

  Meier, Matthias ^a,b   Brand, Johann ^a   Standl, Eberhard ^a   Schnell, Oliver ^a  

^a INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALT INSULIN; INSULIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DEVICE; DRUG ABSORPTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; SKIN ABSCESS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, PARENTERAL; INSULIN; INSULIN INFUSION SYSTEMS; INTESTINAL ABSORPTION; MALE; TIME FACTORS;

EID: 0031851812     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.7.1044     Document Type: Article

References (14)

1. Schnell O, Gerlach E, Hillebrand B, Waker H, Standl E: A case of diabetic pregnancy controlled with a percutaneous access device for intraperitoneal insulin infusion. Diabetes Care 17:1354-1355, 1994
2. Schnell O, Walter H, Gerlach E, Rauch H, Flaschenträger T, Mehnert H, Standl E: Continuous intraperitoneal insulin therapy via port-system in type 1 diabetes with delayed absorption of subcutaneously applied insulin. Diabetes und Stoffwechsel 3:52-58, 1994
3. Husband DJ, Marshall SM, Walford S, Manning I, Wright PD, Alberti KGMM: Continuos intraperitoneal insulin infusion in the management of severely brittle diabetes: a metabolic and clinical comparison with intravenous infusion. Diabet Med 1:99-104, 1984
4. Irsigler K, Kritz H: Alternate routes of insulin delivery Diabetes Care 3: 219-228, 1980
5. Anderson JH, Brunelle RL, Vignati L: Insulin lispro compared to regular insulin in a crossover study involving 1037 patients with type I diabetes (Abstract). Diabetes 44 (Suppl. 1):228A, 1995
6. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J: Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro: a case report. Diabetes Care 20:71-73, 1997
7. Henrichs HR, Unger H, Trautmann ME, Pfützner A: Severe insulin resistance treated with insulin lispro (Letter). Lancet 348:1248, 1996
8. Braimon J, O'Brien M, Kaulbach H, Moses A: The insulin analog lispro effectively treats antibody-mediated insulin resistance (Abstract). Diabetes 45 (Suppl. 2):185A, 1996
9. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
10. Paulsen EP, Courtney JW III, Duckworth WC: Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 28:640-645, 1979
11. Schade DS, Duckworth WC: In search of the subcutaneous insulin resistance syndrome. N Engl Med 315:147-153, 1986
12. Brange J, Owens DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
13. Fineberg NS, Fineberg SE, Anderson JH, Birkett M, Gibson RG, Hufferd S: Does LysPro (B28,29) human insulin analog have altered immunogenicity in patients with type I diabetes? (Abstract) Diabetologia 37 (Suppl. 1): 167, 1994
14. Fineberg SE, Fineberg NS, Anderson JH, Birkett M: Does the use of short acting (LysPro) human insulin in insulin naive patients augment the immune response or differ between type I and type II patients? (Abstract) Diabetes 44 (Suppl. 1):231A, 1995